Quote | Pharming Group N.V. (NASDAQ:PHAR)
Last: | $9.64 |
---|---|
Change Percent: | 3.21% |
Open: | $9.29 |
Close: | $9.34 |
High: | $9.64 |
Low: | $9.29 |
Volume: | 2,554 |
Last Trade Date Time: | 05/14/2024 03:00:00 am |
News | Pharming Group N.V. (NASDAQ:PHAR)
2024-05-12 09:19:10 ET Pharming Group N.V. (PHAR) Q1 2024 Earnings Conference Call May 08, 2024, 7:30 AM ET Company Participants Sijmen de Vries - Executive Director and Chief Executive Officer Stephen Toor - Chief Commercial Officer Anurag Relan - Chief Medical ...
2024-05-08 17:07:15 ET More on Pharming Pharming Group N.V. (PHAR) Q4 2023 Earnings Call Transcript Pharming Group N.V. 2023 Q4 - Results - Earnings Call Presentation Seeking Alpha’s Quant Rating on Pharming Historical earnings data for Pharming ...
Message Board Posts | Pharming Group N.V. (NASDAQ:PHAR)
Subject | By | Source | When |
---|---|---|---|
must see | lifegear | investorshub | 05/09/2023 2:15:22 AM |
just the news we needed | surfkast | investorshub | 05/08/2023 1:43:08 PM |
$PHAR bulls and bears | vladimirr | investorshub | 05/08/2023 11:45:38 AM |
short squeeze signal | jackluna | investorshub | 05/05/2023 5:18:25 PM |
Price now up | SilverFox97 | investorshub | 05/05/2023 4:19:17 PM |
News, Short Squeeze, Breakout and More Instantly...
Pharming Group N.V. Company Name:
PHAR Stock Symbol:
NASDAQ Market:
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...
Recognition given for achievement in commercializing Joenja® (leniolisib), a first-in-class medication brought to market 10 years after disea...
This multinational Phase III study is evaluating leniolisib tablets in children aged 4 to 11 years with APDS, a rare primary immunodeficiency Leid...